	US 12,109,192 B2
	Organic acid addition salts of S-pindolol
Robin Chandra Bhattacherjee, Bedford (GB); Andrew Justin Stewart Coats, Richmond (AU); Elaine Morten, Long Hanborough (GB); Ronnie Maxwell Lawrence, Upper Gravenhurst (GB); Jaclyn Raeburn, Glasgow (GB); Kiara Marissa Lobato, Edinburgh (GB); and Jonathan James Loughrey, Edinburgh (GB)
Assigned to ACTIMED THERAPEUTICS LTD, Ascot (GB)
Appl. No. 17/995,621
Filed by ACTIMED THERAPEUTICS LTD, Ascot (GB)
PCT Filed Mar. 31, 2021, PCT No. PCT/GB2021/050799 § 371(c)(1), (2) Date Oct. 6, 2022, PCT Pub. No. WO2021/205144, PCT Pub. Date Oct. 14, 2021.
Claims priority of application No. 2005112 (GB), filed on Apr. 7, 2020.
Prior Publication US 2023/0190706 A1, Jun. 22, 2023
Int. Cl. A61K 31/404 (2006.01); A61K 31/192 (2006.01); A61K 31/194 (2006.01)

CPC A61K 31/404 (2013.01) [A61K 31/192 (2013.01); A61K 31/194 (2013.01)]

11 Claims

1. A pharmaceutically acceptable acid addition salt of:

(i) S-pindolol; and

(ii) benzoic acid,

wherein the salt is S-pindolol benzoate; and

wherein:

the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 1 having an x-ray powder diffraction pattern comprising peaks at 8.1°, 11.4°, 12.5°, 12.8°, 15.4° and 17.0°±0.2°2θ; or

the S-pindolol benzoate is in the form of S-pindolol benzoate crystalline polymorph Pattern 2 having an x-ray powder diffraction pattern comprising peaks at 16.9°, 18.9° and 20.1°±0.2°2θ.